Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields

Nenhuma Miniatura disponível
Citações na Scopus
70
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
COSTA, F. P.
MORGAN, D.
CANTOR, A.
Citação
BRITISH JOURNAL OF CANCER, v.105, n.5, p.640-648, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BACKGROUND: Therapeutic options for patients with advanced hepatocellular carcinoma (HCC) are limited. There is emerging evidence that the growth of cancer cells may be altered by very low levels of electromagnetic fields modulated at specific frequencies. METHODS: A single-group, open-label, phase I/II study was performed to assess the safety and effectiveness of the intrabuccal administration of very low levels of electromagnetic fields amplitude modulated at HCC-specific frequencies in 41 patients with advanced HCC and limited therapeutic options. Three-daily 60-min outpatient treatments were administered until disease progression or death. Imaging studies were performed every 8 weeks. The primary efficacy end point was progression-free survival >= 6 months. Secondary efficacy end points were progression-free survival and overall survival. RESULTS: Treatment was well tolerated and there were no NCI grade 2, 3 or 4 toxicities. In all, 14 patients (34.1%) had stable disease for more than 6 months. Median progression-free survival was 4.4 months (95% CI 2.1-5.3) and median overall survival was 6.7 months (95% CI 3.0-10.2). There were three partial and one near complete responses. CONCLUSION: Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows evidence of antitumour effects in patients with advanced HCC. British Journal of Cancer (2011) 105, 640-648. doi:10.1038/bjc.2011.292 www.bjcancer.com Published online 9 August 2011 (C) 2011 Cancer Research UK
Palavras-chave
hepatocellular carcinoma, phase II study, radiofrequency electromagnetic fields, tumour-specific modulation frequencies, 27.12 MHz
URI
https://observatorio.fm.usp.br/handle/OPI/22474
Referências
  1. Amato D, 1994, COMPR THER, V20, P681
  2. Amato David, 1993, Comprehensive Therapy, V19, P242
  3. Pasche B, 1996, SLEEP, V19, P327
  4. Cance WG, 2000, CANCER, V88, P912, DOI 10.1002/(SICI)1097-0142(20000215)88:4<912::AID-CNCR23>3.0.CO;2-T
  5. Riaz A, 2009, J CLIN ONCOL, V27, P5734, DOI 10.1200/JCO.2009.23.1282
  6. Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
  7. Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
  8. Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
  9. Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X
  10. Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep20933
  11. Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
  12. Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1
  13. Siegel AB, 2008, J CLIN ONCOL, V26, P2992, DOI 10.1200/JCO.2007.15.9947
  14. Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
  15. Chan SL, 2009, J CLIN ONCOL, V27, P446, DOI 10.1200/JCO.2008.18.8151
  16. Llovet JM, 2008, J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134
  17. Jemal A, 2004, CA-CANCER J CLIN, V54, P8
  18. Thomas MB, 2005, J CLIN ONCOL, V23, P2892, DOI 10.1200/JCO.2005.03.196
  19. Abou-Alfa GK, 2006, J CLIN ONCOL, V24, P4293, DOI 10.1200/JCO.2005.01.3441
  20. Barbault A, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-51
  21. Boige V, 2007, BRIT J CANCER, V97, P862, DOI 10.1038/sj.bjc.6603956
  22. Chang Isaac, 2003, Biomed Eng Online, V2, P12, DOI 10.1186/1475-925X-2-12
  23. Choi BI, 2007, HEPATOL RES, V37, pS172, DOI 10.1111/j.1872-034X.2007.00182.x
  24. Chuah B, 2007, ACTA ONCOL, V46, P234, DOI 10.1080/02841860600702076
  25. Cohn AL, 2008, INVEST NEW DRUG, V26, P381, DOI 10.1007/s10637-008-9124-5
  26. Dollinger MM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-72
  27. Ahlbom A, 1998, HEALTH PHYS, V74, P494
  28. KASSIANIDES C, 1987, GASTROENTEROL CLIN N, V16, P553
  29. Kelly TL, 1997, STRESS MEDICINE, V13, P251, DOI 10.1002/(SICI)1099-1700(199710)13:4<251::AID-SMI750>3.0.CO;2-0
  30. Maruyama H, 2008, WORLD J GASTROENTERO, V14, P1710, DOI 10.3748/wjg.14.1710
  31. Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
  32. Pasche B, 2003, BIOELECTROMAGNETIC M, P321
  33. PASCHE B, 1990, NEW ENGL J MED, V323, P486
  34. Reite M., 1994, Bioelectromagnetics, V15, P67, DOI 10.1002/bem.2250150110
  35. SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/44
Carregar mais